Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas

Mirco Friedrich,Roman Sankowski,Lukas Bunse,Michael Kilian,Edward Green,Carina Ramallo Guevara,Stefan Pusch,Gernot Poschet,Khwab Sanghvi,Markus Hahn,Theresa Bunse,Philipp Münch,Hagen M. Gegner,Jana K. Sonner,Anna von Landenberg,Frederik Cichon,Katrin Aslan,Tim Trobisch,Lucas Schirmer,Denis Abu-Sammour,Tobias Kessler,Miriam Ratliff,Daniel Schrimpf,Felix Sahm,Carsten Hopf,Dieter H. Heiland,Oliver Schnell,Jürgen Beck,Chotima Böttcher,Camila Fernandez-Zapata,Josef Priller,Sabine Heiland,Ilona Gutcher,Francisco J. Quintana,Andreas von Deimling,Wolfgang Wick,Marco Prinz,Michael Platten

DOI: https://doi.org/10.1038/s43018-021-00201-z

IF: 22.7

2021-05-24

Nature Cancer

Abstract:Abstract The dynamics and phenotypes of intratumoral myeloid cells during tumor progression are poorly understood. Here we define myeloid cellular states in gliomas by longitudinal single-cell profiling and demonstrate their strict control by the tumor genotype: in isocitrate dehydrogenase (IDH)-mutant tumors, differentiation of infiltrating myeloid cells is blocked, resulting in an immature phenotype. In late-stage gliomas, monocyte-derived macrophages drive tolerogenic alignment of the microenvironment, thus preventing T cell response. We define the IDH-dependent tumor education of infiltrating macrophages to be causally related to a complex re-orchestration of tryptophan metabolism, resulting in activation of the aryl hydrocarbon receptor. We further show that the altered metabolism of IDH-mutant gliomas maintains this axis in bystander cells and that pharmacological inhibition of tryptophan metabolism can reverse immunosuppression. In conclusion, we provide evidence of a glioma genotype-dependent intratumoral network of resident and recruited myeloid cells and identify tryptophan metabolism as a target for immunotherapy of IDH-mutant tumors.